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Conclusions: Carboplatin and vinorelbine administered i.v. and orally 
induce fewer responses than previously reported with cisplatin plus i.v. 
vinorelbine, though with overlapping 95% conﬁdence intervals. The 
current patient population had a high frequency of adverse prognostic 
variables such as poor performance status, stage 4 disease, non-epithe-
lial subtype and advanced age, reﬂecting the population of MPM usu-
ally seen in the community but considerably worse than those usually 
included in recently published trials of doublet chemotherapy. As such, 
it is noteworthy that the median survival is in excess of 9 months (me-
dian not yet reached).The regimen was easy to administer and generally 
well tolerated without any toxic deaths in spite of the poor prognostic 
patient population. Quality of life data is being analysed and should be 
compared to that of other regimens. 
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Background: Malignant mesotheliomas is increasing in Japan and 
other countries. However, the accurate pathological diagnosis of pleural 
or peritoneal mesothelioma is sometimes difﬁcult if adequate histologi-
cal and immunohistochemical analyses are undertaken. The aim of this 
study is to clarify the useful antibodies panel for distinguishing perito-
neal epithelioid mesothelioma (PEM) from ovarian carcinomas (serous 
papillary adenocarcinoma (SC) and clear cell adenocarcinomas (CC) 
Materials and Methods: Twenty-three peritoneal mesotheliomas, 16 
clear cell adenocarciomas and 20 serous papillary adenocarcinomas 
were obtained from our surgical pathology ﬁles. The immunohisto-
chemistry was undertaken using commercially available antibodies. 
The immunohistochemical scoring is semi-quantiﬁed as follows, 0, 
none or trace, 1, less than 5% tumor cells are positive, 2, 5-50% tumor 
cells are positive, and 3, more than 51% tumor cells are positive.
Results and Discussion: The positivity for each antibody in PEM, 
CC, and SC were as follows; 1) calretinin (PEM; CC; SC, 100%; 31%; 
40%), 2) WT1 (89%, 19%, 90% ), 3) thrombomodulin (94%, 38%, 
5%), 4) CK5/6 (89%, 44%, 80%), 5) D2-40 (94%, 31%, 45%), 6) CEA 
(0%, 50%, 35%), 7) CA19-9 (17%, 91%, 80%), 8) BerEP4 (0%, 94%, 
100%), 9) MOC31 (6%, 100%, 90%), 11) Napsin A (0%, 75%, 5%), 
12) ER (0%, 31%, 80%) 13) CD15 (0%, 94%, 60%). 
The degree of positive intensity of calretinin, D2-40, thrombomodulin 
in PEM was signiﬁcantly higher, and CEA, CA19-9, MOC31, BerEP4, 
CD15 and ER was signiﬁcantly lower than those in SC or CC. 
These results suggested that the combinations of positive markers (cal-
retinin, thrombomodulin, and D2-40) and negative markers (BerEP4, 
MOC31, CD15 and ER) is useful for differential diagnosis for these 
tumors. WT1 reported as “positive marker” is not able to use for dif-
ferential diagnosis between PEM and SC.
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Primary malignant lymphoreticular diseases of the lung form nearly 
0.5% primary lung tumours. In this group there is primary non-Hodg-
kin lymphoma of the lung, which is so rare to constitute 0.34% of all 
non-Hodgkin lymphomas. Choice of therapy in localised lesions is the 
resection. In this study it was aimed to deﬁne this rare disease.
In radiological examination of a 40 year-old male patient with effort-
induced dyspnea complaint had inﬁltrative appearance in upper lobe 
of right lung. This patient was found negative in regard of tuberculosis 
investigation and there was not any response to non-speciﬁc antibiotic 
therapy. At least, it was diagnosed primary lymphoma of the lung by 
transthoracic thin needle biopsy. Any pathology could not be deter-
mined during research of other systems.
In the patient to whom right posterolateral thoracotomy was performed, 
it was seen that tumours of upper lobe had been invaded into the 
middle lobe and so upper bilobectomy was done. There was not any 
complication in the postoperative period of this patient whose pathol-
ogy reporting “right upper and middle lobe MALT type marginal zone 
lymphoma”. According to Modiﬁed Ann Arbor Staging System it was 
determined as Stage IE and this patient was taken into follow-up pro-
gramme in our clinical.
We believe that in the differential diagnosis of nodular or inﬁltrative 
lesions of the lung not responding to medical therapy, we should take 
primary lung lymphoma into consideration and in localised lesions 
surgical therapy should be applied. 
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Malignant mesothelioma is a highly aggressive kind of tumor with a 
poor prognosis and a limited response to chemotherapy. Pemetrexed 
disodium (Alimta), which is a multi-targeted antimetabolite inhibiting 
the folate pathway, has demonstrated promising clinical activity in a 
wide variety of solid tumors including mesothelioma.
An 81-year old female patient was admitted to our hospital with cough 
and dyspnea. A massive unilateral pleural effusion and multiple pleural 
nodules were determined by a thorax computed tomography (TCT). 
She had the diagnosis of mesothelioma after an open lung biopsy. The 
patient had recieved radiotherapy for her primary tumor ﬁrstly. After-
wards, she had been observed for eighteen months without any symp-
toms since she had a new complaint of effort dyspnea. In the new TCT, 
there were multiple pleural nodules, massive pleural effusion in right 
hemithorax, mediastinal lymph nodes with pathological sizes and an 
underskin mass localized at the previous biopsy region; which had been 
interpreted as progression of primary tumor. It was decided to give 
chemotherapy containing pemetrexed (Alimta) 500 mg/m2 and cisplatin 
